Stay updated on Nivolumab and BMS-986253 in Prostate Cancer Clinical Trial
Sign up to get notified when there's something new on the Nivolumab and BMS-986253 in Prostate Cancer Clinical Trial page.

Latest updates to the Nivolumab and BMS-986253 in Prostate Cancer Clinical Trial page
- Check4 days agoNo Change Detected
- Check12 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.8%
- Check19 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.1%
- Check26 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check33 days agoChange DetectedThe web page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference1%
- Check62 days agoChange DetectedThe webpage has updated key results reporting dates and participant statistics related to prostate-specific antigen (PSA) recurrence, with a focus on new reporting dates and the number of participants involved in the study.SummaryDifference4%
- Check76 days agoChange DetectedThe webpage has been updated to reflect a new study on prostate cancer, including the addition of collaborators and a revision number, while significant details about the study's design and objectives have been removed.SummaryDifference45%
Stay in the know with updates to Nivolumab and BMS-986253 in Prostate Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab and BMS-986253 in Prostate Cancer Clinical Trial page.